Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 1/2 2Phase 1 1

Status

Terminated 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 5NIH 2OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × oregovomab × Clear all
NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

CanariaBio Inc.

Phase 2 Active not recruiting
10 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05605535 2026-04-01

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

CanariaBio Inc.

Phase 2 Active not recruiting
88 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01616303 2020-09-14

A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer

Quest PharmaTech Inc.

Phase 2 Completed
97 enrolled
Gynecologic

Adenocarcinoma, Neoplasms, Ovarian Neoplasms

NCT00034372 2007-12-18

Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma

Unither Pharmaceuticals

Phase 2 Terminated
102 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00086632 2007-12-18

Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

Unither Pharmaceuticals

Phase 2 Terminated
40 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡